Trial reportLeukemia2023
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
Open access · hybridAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
13.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 48 citations in OpenAlex.
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- Deconvoluting the multi-faceted roles of alternative splicing events in cancer: From underlying mechanisms to innovative therapeutics.Acta pharmaceutica Sinica. B · 2026Review
- Review
- Assessing the Stability of Molecular Glues with Weighted Ensemble Simulations.Journal of chemical theory and computation · 2026Article
- Targeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery.International journal of molecular sciences · 2026Review
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- Molecular and therapeutic frontiers in anemia therapy.The Journal of clinical investigation · 2026Review
- Targeting "undruggable" cancer proteins: pharmacological challenges and emerging strategies.Translational cancer research · 2026Review
- Review
- Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunities.Acta pharmaceutica Sinica. B · 2026Review
- Induced proximity-based therapeutic modalities.Nature reviews. Drug discovery · 2026Review
- A Novel Paradigm for Targeting Challenging Targets: Advancing Technologies and Future Directions of Molecular Glue Degraders.Molecules (Basel, Switzerland) · 2026Review
- Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer.Oncology research · 2026Review
- Unlocking the undruggable spliceosome: generative AI and structural dynamics in cancer therapy.Frontiers in cell and developmental biology · 2026Review
- RNA Splicing as a Therapeutic Target in Cancer.Annual review of pharmacology and toxicology · 2026Review
- Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy.Biomarker research · 2025Review
- RNA Splicing as a Therapeutic Vulnerability in Therapy-Refractory Multiple Myeloma.Blood cancer discovery · 2025Article
- Review
- Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications.Current hematologic malignancy reports · 2025Review
- Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells.Biomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Jan Philipp Bewersdorf *Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3352-0902
Maximilian Stahl *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Justin TaylorLeukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.ORCID http://orcid.org/0000-0003-4407-6325
Xiaoli MiDepartment of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Namrata Sonia ChandhokLeukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Justin WattsLeukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Andriy DerkachDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mateusz WysockiDepartment of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sydney X LuMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jessie BourcierMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0009-0008-2499-6064
Simon J HoggMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3170-839X
Jahan RahmanMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sana ChaudhryLeukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Tulasigeri M TotigerLeukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Omar Abdel-Wahab *Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. abdelwao@mskcc.org.
Eytan M Stein *Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. steine@mskcc.org.
Memorial Sloan Kettering Cancer Center · USUniversity of Miami · USDana-Farber Cancer Institute · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MThe Memorial Sloan Kettering Cancer Center SPORE in LeukemiaP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eytan Stein · 2021 to 2026
$16.8MGenetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0MInterrogating the minor spliceosome to understand and treat leukemiaR01CA251138 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, BRADLEY, ROBERT K · 2020 to 2024
$3.3MTargeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA254838NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA251138NHLBI NIH HHS R01 HL128239
Abstract
PubMed holds no abstract for this paper.
Indexed as
NeoplasmsHumansIndolesRNA SplicingRNA Splicing FactorsSulfonamidesIndolesN-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamideRNA Splicing FactorsSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.